Raptor Pharmaceutical Reports First Quarter 2014 Financial Results and Provides Corporate Update
May 08, 2014 16:05 ET
|
Raptor Pharmaceutical Inc
Reports PROCYSBI® net product sales of $12.1 million in first quarter 2014 and launch of PROCYSBI® in Germany
Company to host conference call and webcast today at 4:30 p.m. EDT...
Raptor Pharmaceutical to Present at Upcoming Investor Conference
May 01, 2014 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., May 1, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at the Bank of America Merrill Lynch 2014 Health Care...
Raptor Pharmaceutical Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Corporate Update
March 13, 2014 16:05 ET
|
Raptor Pharmaceutical Inc
2014 guidance of $55-$65 million of net sales for PROCYSBI®
Company to host conference call and webcast today at 4:30 p.m. EDT
NOVATO, Calif., March 13, 2014 (GLOBE NEWSWIRE) -- Raptor...
Raptor Pharmaceutical to Hold Fourth Quarter and Full Year 2013 Financial Results Webcast and Conference Call
March 10, 2014 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., March 10, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release fourth quarter and full year 2013 financial results after market close...
Raptor Pharmaceutical to Present at Two Upcoming Investor Conferences
February 24, 2014 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at two upcoming investor conferences.
JMP...
Raptor Announces Full Enrollment of Phase 2b Trial of RP103 for Non-Alcoholic Fatty Liver Disease in Children
January 13, 2014 07:00 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that its Phase 2b clinical trial, to evaluate the safety and potential efficacy of RP103...
Raptor Submits IND for RP103 for Leigh Syndrome and Other Mitochondrial Disorders
December 10, 2013 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Dec. 10, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has submitted an investigational new drug application (IND) to the U.S. Food and...
Raptor Pharmaceutical Corp. Provides PROCYSBI(R) Launch Update and Third Quarter 2013 Financial Results
November 07, 2013 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today provided financial results for its third quarter and nine months ended September 30, 2013.
PROCYSBI...
Raptor Pharmaceuticals and DaVita Clinical Research Launch Screening Program to Identify Patients With Late Onset Nephropathic Cystinosis
October 23, 2013 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) and DaVita Clinical Research® (DCR®) (NYSE:DVA) today announced a collaboration to screen blood...
Raptor Pharmaceutical to Hold Third Quarter 2013 Financial Results Webcast and Conference Call
October 21, 2013 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release third quarter 2013 financial results after market close on Thursday,...